Oxygenta Pharmaceutical has informed that the Board of Directors of the Company at its just concluded meeting has, transacted the following items of business: Approved the Un-Audited financial results for the First Quarter ended on 30th June, 2023; Took note of the Limited Review Report on Un-Audited financial results for the first quarter ended on 30th June, 2023 issued by the Statutory Auditors of the Company; Accepted the resignation of statutory auditors of the company Gowri Shankar and Associates. Disclosure as per regulation 30 of SEBI (LODR) regulations, 2015 has already been given; Disclosure under Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 copy enclosed as Annexure-I. The meeting commenced at 04.00 PM and concluded at 04.30 PM.
The above information is a part of company’s filings submitted to BSE.
